You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline

You are reading 1 of 2 free-access articles allowed for 30 days

Trinity-led nano-medicine project wins major European award

By Mindo - 01st Jul 2015 | 4 views

The winning project called NAMDIATREAM involves the development of nanotechnology-based tools to enable early detection and imaging of molecular biomarkers of the most common cancer types and of cancer which has spread. It also helps to identify cells which indicate early-stage disease onset.

The project is built on the innovative technology concepts of super-sensitive ‘lab-on-a-bead’, ‘lab-on-a-chip’ and ‘lab-on-a-wire’ nano-devices.

Professor of Molecular and Translational Medicine,Yuri Volkov of the School of Medicine and AMBER Investigator, and Dr Adriele Prina-Mello, Department of Clinical Medicine, School of Medicine and AMBER Investigator, led the project.

The project has developed technologies which have been integrated into diagnostic systems for the detection of cancer cells and molecular markers. Their work with the interdisciplinary project consortium has demonstrated that the performance of these new technologies is comparable or superior to the quality obtained with gold standard protocols of diagnostic practice.

Commenting on the win and the significance of the project, Prof Volkov said: “We are delighted that our project has been selected as the best by EuroNanoForum 2015 amongst over 1,000 projects launched in this field. Cancer is a disease of uncontrolled growth of human cells. While scientists are able today to manipulate extremely small nano-objects, amazingly, we sometimes still can’t see even much larger structures, such as cancer cells, early enough to find their location in the human body, target and kill them, thereby saving patients’ lives.

“In the NAMDIATREAM project, we created highly sensitive probes using a number of strategic nanoparticles which enable us to detect not only whole tumours but also single cancer cells which have spread and even cancer molecules in the blood. Integrating these multi-functional probes into new diagnostic devices will give us a much higher quality kind of diagnostic tool which can be used for both traditional biopsies and to analyse liquid samples such as blood.”

Dr Sergio Fernandez-Ceballos, National Delegate for H2020 in the area of Nanotechnologies and Advanced Materials at Enterprise Ireland said: “NAMDIATREAM has been the biggest win to Ireland in Framework Programme 7 under the Nanotechnology and Advanced materials programme. This project is an example of academics and industry coming together to develop early cancer detection tools which will be commercialised and exploited by members of the consortium.”


Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read